🇺🇸 ABBV — AbbVie Inc.

Salud Compra
← Volver

Precio actual

286,00 USD

Máx. histórico

294,89

4 días

Caída desde máximo

-3,01%

Rango 52 semanas

190,75 – 298,74

Variación hoy

-0,98%

Cierre anterior

288,84

Rango de hoy

284,71 – 291,32

Volumen hoy

5.348.839

Peor caída histórica

-45,09%

26/01/2018 → 15/08/2019

Recuperado en 477 días

Volatilidad anualizada ⓘ

26,29%

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
49,14 (puede no estar actualizado)
Dividend yield
2,40% (puede no estar actualizado)
Precio objetivo analistas
306,42 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 22 horas
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,9200 USD · Yield: 2,42%
Fecha de pago Importe por participación
15/10/2026 1,7300 USD
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
25/02/2015 61,10 61,10 60,21 60,62 -0,41% 1,46% 9.983.900
24/02/2015 60,85 61,30 60,52 60,87 +0,50% 1,28% 7.900.700
23/02/2015 61,54 61,90 60,24 60,57 -1,19% 2,70% 11.582.700
20/02/2015 59,61 61,34 59,22 61,30 +3,90% 3,56% 15.534.000
19/02/2015 58,92 59,08 58,65 59,00 -0,41% 0,73% 8.665.500
18/02/2015 59,15 59,48 58,31 59,24 +0,89% 1,98% 10.781.700
17/02/2015 58,95 59,00 57,90 58,72 +1,15% 1,87% 12.789.700
13/02/2015 57,35 58,10 56,90 58,05 +1,75% 2,09% 11.303.200
12/02/2015 57,40 57,58 56,16 57,05 +0,64% 2,47% 11.940.900
11/02/2015 57,36 57,83 56,26 56,69 -0,35% 2,74% 14.681.600
10/02/2015 55,93 57,01 55,60 56,89 +2,54% 2,52% 18.917.000
09/02/2015 55,67 56,35 55,18 55,48 -2,50% 2,10% 22.522.000
06/02/2015 57,71 57,83 56,69 56,90 -1,88% 1,98% 13.890.900
05/02/2015 57,55 58,26 56,15 57,99 +1,90% 3,67% 18.964.700
04/02/2015 58,95 58,95 56,65 56,91 -7,69% 3,90% 31.250.600
03/02/2015 61,60 61,76 59,98 61,65 +1,57% 2,89% 10.721.800
02/02/2015 61,49 61,49 58,65 60,70 +0,58% 4,62% 11.491.100
30/01/2015 62,09 62,68 60,12 60,35 -4,39% 4,12% 17.582.500
29/01/2015 62,12 63,38 61,59 63,12 +2,05% 2,88% 8.485.600
28/01/2015 63,44 63,56 61,69 61,85 -1,98% 2,95% 6.910.100
27/01/2015 62,33 63,50 62,20 63,10 +0,43% 2,09% 6.532.300
26/01/2015 62,26 63,04 61,68 62,83 +0,64% 2,18% 8.181.100
23/01/2015 63,66 63,66 62,35 62,43 -0,87% 2,06% 6.881.100
22/01/2015 63,20 63,45 61,88 62,98 +0,45% 2,48% 8.941.700
21/01/2015 63,10 63,45 62,28 62,70 -1,18% 1,85% 7.979.500
20/01/2015 65,06 65,29 62,75 63,45 -1,69% 3,90% 9.065.300
16/01/2015 62,95 64,62 62,64 64,54 +2,62% 3,15% 8.106.000
15/01/2015 64,00 64,11 62,87 62,89 -1,27% 1,94% 6.149.100
14/01/2015 62,62 64,07 61,86 63,70 +0,49% 3,53% 9.448.300
13/01/2015 65,72 66,07 62,91 63,39 -3,60% 4,81% 13.908.400